A population-based analysis of outcomes for small cell carcinoma of the breast by tumor stage and the use of radiation therapy

Hare, Felicia; Giri, Smith; Patel, Jashmin K; Hahn, Andrew W.; Martin, Michael

doi:10.1186/s40064-015-0913-y

Cited by 27 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small cell carcinoma of the breast has been very rarely reported in the literature [ 8 – 11 ]. The largest population-based series, by Hare et al ., included 199 patients with small cell carcinoma of the breast, who were compared with patients with small cell lung carcinoma [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Primary small cell carcinoma of the breast: a case report

et al. 2017

View full text Add to dashboard Cite

BackgroundNeuroendocrine breast cancer is a rare entity that was defined in 2003 by the World Health Organization as a separate breast cancer subtype. The diagnosis of neuroendocrine breast cancer requires the presence of neuroendocrine features in at least 50% of malignant cells, the exclusion of non-mammary primary tumors, as well as the presence of an in situ component in breast histology. The treatment and prognosis of neuroendocrine breast cancer are still not well established. Small cell carcinoma of the breast is a subtype of neuroendocrine cancer, resembling small cell carcinoma of the lung. It has a very poor prognosis and warrants treatment with platinum-based chemotherapy.Case presentationWe herein report the case of a 47-year-old white woman with a left breast mass that was found to be an early-stage, high-grade small cell carcinoma of the breast. Positron emission tomography-computed tomography imaging excluded any other primary disease. Our patient underwent a left total mastectomy with sentinel lymph node biopsy and received cisplatin-based adjuvant chemotherapy. Our patient remains free of disease to date.ConclusionsThis case report sheds light on a rarely described disease and provides a comprehensive approach to diagnosis and management. Neuroendocrine carcinoma of the breast is a well-defined histologic subtype of breast cancer. Small cell carcinoma of the breast is a rare subtype of neuroendocrine breast cancer. Due to the rarity of this entity, prognosis has still not been well established, and treatment has not been standardized, cisplatin-based treatment has been used in this case similar to small cell carcinoma of the lung.

show abstract

Section: Introductionmentioning

confidence: 99%

Primary small cell carcinoma of the breast: a case report

et al. 2017

View full text Add to dashboard Cite

show abstract

“…While similar characteristics between small cell carcinoma of the lung and small cell carcinoma of the breast are seen, there may be inherent biologic differences. Options for treatment of small cell carcinoma of the breast include surgery, adjuvant chemotherapy and radiation, and hormonal therapy with the options dependent on the stage and expression of receptors [1,8]. Due to the paucity of data, the optimal management of small cell carcinoma of the breast remains unknown.…”

Section: Introductionmentioning

confidence: 98%

“…Small cell carcinoma of the breast accounts for 2-5 % of all breast cancer [5]. A population-based study of small cell carcinoma in the United States from 1992 to 2010 showed that extrapulmonary small cell carcinoma is associated with a more favorable stage-specific patient survival [6]; specifically, small cell carcinoma of the breast has a more favorable prognosis for localized and regional disease than small cell carcinoma of the lung [1].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

McCullar

Pandey

Yaghmour

et al. 2016

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

Small cell carcinoma of the breast is a rare, aggressive form of breast cancer that is associated with extremely poor outcomes [1]. In an effort to identify possible targets for treatment, we utilized comprehensive genomic profiling in small cell carcinoma of the breast. Under an IRB approved protocol, we identified patients with small cell carcinoma of the breast and small cell carcinoma of the lung profiled by Caris Life Sciences between 2007 and 2015. Tumors were assessed with up to 25 immunohistochemical stains, in situ hybridization of cMET, EGFR, HER2, PIK3CA, and TOP2A, and next generation sequencing as well as Sanger sequencing of 47 genes. 19 patients with small cell carcinoma of the breast were identified, median age was 58 years (range 37-79) and 42 % had metastatic disease at presentation; for comparison, 58 patients with small cell carcinoma of the lung were identified (66 [36-86], 65 % metastatic). By immunohistochemistry, 31 % of small cell carcinoma of the breast patients expressed ER, 13 % expressed PR, and 16 % expressed AR; small cell carcinoma of the lung patients expressed ER 0 %, PR 2 %, and AR 6 %. Small cell carcinoma of the breast and small cell carcinoma of the lung patients had similar patterns of other immunohistochemical expression (0 v 0 % PDL1, 50 v 42 % PD1, and 77 v 95 % TOP2A, respectively). All small carcinoma of the breast and small cell carcinoma of the lung patients were negative for HER2 and cMET amplification by in situ hybridization. Next generation sequencing revealed TP53 mutations in 75 % of patients both with small cell carcinoma of the breast and small cell carcinoma of the lung and PIK3CA mutations in 33 % of small cell carcinoma of the breast patients but no small cell carcinoma of the lung patients (Fisher's exact test p = 0.005, OR 0.02 [0.00-0.52]). No other mutations were found in small cell carcinoma of the breast patients and no other mutation occurred in over 10 % of small cell carcinoma of the lung patients except RB1 in 19 % (p = 0.31). Small cell carcinoma of the breast is an aggressive tumor with few therapeutic options. Molecular profiling suggests many similarities between small cell carcinoma of the breast and small cell carcinoma of the lung with the exception an increased incidence of PIK3CA mutations in small cell carcinoma of the breast, which may have therapeutic implications.

show abstract

“…15,17 Adjuvant hormonal therapy is added if the tumor expresses the appropriate receptors. 6,15,17 However, there is no consensus and no trials comparing these 2 chemotherapeutic strategies. Most studies have shown that high-grade neuroendocrine carcinomas of the breast are very aggressive neoplasms, having poorer prognosis than the more common ductal and/or lobular infiltrating carcinomas.…”

Section: Discussionmentioning

confidence: 99%

High-Grade Neuroendocrine Carcinoma of the Breast With Focal Squamous Differentiation

et al. 2016

View full text Add to dashboard Cite

Primary neuroendocrine carcinoma of the breast is a rare tumor that comprises less than 1% of breast carcinomas, with most patients being in the sixth or seventh decade of their life. In this article, the authors present the case report of a 42-year-old woman with a rapidly growing tumor in her right breast. After clinical staging by physical examination, breast imaging, and thoracoabdominal computed tomography the patient underwent breast-conserving surgery. The histologic results showed a unique type of high-grade, predominantly large-cell neuroendocrine carcinoma with focal abrupt squamous differentiation. The authors also discuss the clinical and morphological characteristics of the tumor as well as treatment options.

show abstract

A population-based analysis of outcomes for small cell carcinoma of the breast by tumor stage and the use of radiation therapy

Cited by 27 publications

References 24 publications

Primary small cell carcinoma of the breast: a case report

Primary small cell carcinoma of the breast: a case report

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

High-Grade Neuroendocrine Carcinoma of the Breast With Focal Squamous Differentiation

Contact Info

Product

Resources

About